GlassScriptPhysician profile
Brian Kuronya
NPI 1831202654
$26,635.00
in general payments reported to CMS, 2019-2025
76 companies · $5,070 in 2025
The $5,070 reported for 2025 was more than what 99% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,529 · 2020: $2,287 · 2021: $3,827 · 2022: $3,615 · 2023: $4,080 · 2024: $5,228 · 2025: $5,070.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $14K · Education: $321.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $14,056.49 |
| Education | $320.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $3,124.24 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Abbvie INC. | $2,599.53 | 2019-2025 | |
| Novo Nordisk INC | $2,460.96 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Amgen INC. | $1,802.71 | 2019-2025 | Otezla, Repatha, Evenity |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,783.42 | 2019-2025 | Jardiance, Synjardy, Stiolto Respimat |
| Pfizer INC. | $1,741.20 | 2019-2025 | |
| Lilly USA, LLC | $1,501.72 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Astellas Pharma US INC | $1,369.97 | 2019-2025 | Veozah, Myrbetriq, Vesicare |
| Merck Sharp & Dohme LLC | $815.47 | 2019-2025 | Gardasil 9, Vaxneuvance, M-M-R II |
| Otsuka America Pharmaceutical, INC. | $800.08 | 2022-2025 | Rexulti, Abilify Maintena |
| Lundbeck LLC | $628.84 | 2020-2025 | Rexulti |
| Bayer Healthcare Pharmaceuticals INC. | $609.37 | 2022-2025 | |
| Allergan, INC. | $536.12 | 2019-2020 | |
| Exact Sciences Corporation | $442.78 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Paratek Pharmaceuticals, INC. | $370.89 | 2021-2025 | Nuzyra, Xhance |
Show all 76 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Kuronya listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.